Beam Therapeutics IncBEAM
Price$24.39Intrinsic value$43.0877% above price

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
13analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY EPS (est.)
-$4.45next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly1.2BTarget: Sufficient to fund operations into mid-2029
BEAM-302 (AATD) Pivotal Cohort Enrollment Annually
Risto-cel (BEAM-101) BLA Submission Progress AnnuallyTarget: Submit Biologics License Application (BLA) as early as year-end 2026
Watch Items
  • Risto-cel (BEAM-101) BLA Submission Timeline
  • BEAM-302 Pivotal Cohort InitiationTrigger: Failure to initiate pivotal cohort in H2 2026
  • BEAM-304 IND Clearance and Phase 1/2 Trial Initiation
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.